As India’s First New Chemical Entity, a research molecule from Zydus, Lipaglyn takes the responsibility of shaping the Market of Atherogenic Diabetic Dyslipidemia (ADD) with the objective of providing better solution to healthcare professionals in managing the unmet needs in management of ADD (Atherogenic Diabetic Dyslipidemia) & associated NAFLD ( Non Alcoholic Fatty Liver Disease).

ADD has a strong prevalence across the country and affects every 1 out of 3 Indians with high TG (triglyceride) levels, while NAFLD affects 70% of all Diabetics whereby it is deemed as a silent killer since it causes 63% higher CV (cardiovascular) mortality.

The digital initiatives like IJADD (International Journal of Atherogenic Diabetic Dyslipidemia) and IJADD Expert Opinion webinar series led by the eminent KOLs (Key Opinion Leaders) across Pan India has vastly contributed in highlighting merits of Lipaglyn and helped the nation blow the whistle against ADD & NAFLD.

Blow the Whistle Campaign for this under-diagnosed ailment  has also attracted over 20000 footfalls visiting the dedicated therapy pages on the online journal website ijadd.com, with special access to articles and webinars, rendering a special focus on the therapy areas.

All the therapy shaping initiatives were coupled with field passion and the emotional bonding ignited with “Be Vocal For Local” Campaign. A special focus on therapy shaping initiatives with the advent of India’s 1st Drug to be approved by DCGI (Drugs Controller General of India) for NAFLD makes this campaign vital since this research molecule from India has good phase 3 trial results wrt efficacy and safety published in reputed journals  making it “Practically Perfect in Every Way in NAFLD treatment”.